Episode Details

Back to Episodes
A New Target for Protecting the Optic Nerve? Human Glaucoma Study Strengthens the Case Against Galectin-3

A New Target for Protecting the Optic Nerve? Human Glaucoma Study Strengthens the Case Against Galectin-3

Published 2 months, 4 weeks ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/a-new-target-for-protecting-the-optic-nerve-human-glaucoma-study-strengthens-the-case-against-galectin-3

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

A New Target for Protecting the Optic Nerve? Human Glaucoma Study Strengthens the Case Against Galectin-3 Introduction Galectin-3 inhibition is becoming one of the more credible new neuroprotective strategies in glaucoma—but it is not yet a proven treatment, and it is not ready to replace intraocular pressure lowering. The reason for the growing interest is that Galectin-3 sits at the intersection of several processes implicated in glaucoma: Microglial activation Müller glial stress responses Astrocyte reactivity Neuroinflammation Phagocytosis and debris clearance Metabolic dysfunction Retinal ganglion-cell and optic-nerve injury Earlier animal studies showed that genetic removal or pharmacological inhibition of Galectin-3 could preserve retinal ganglion cells and their axons despite continued ocular hypertension. A later rat study confirmed that intravitreal TD139, a small-molecule Galectin-3 inhibitor, protected retinal ganglion cells without lowering intraocular pressure. () The important new development is the demonstration that Galectin-3 is strongly associated with Müller glia in human glaucomatous retinas, rather than being merely a marker of activated microglia in experimental animals. The human finding makes the target more biologically relevant to patients, but it also makes the biology more complicated: Galectin-3 may be harmful in some disease-associated microglia while supporting beneficial Müller-cell functions in other circumstances. An Important Evidence Check: What Was Actually Published? As of August 17, 2026, the directly verifiable record matching the human Müller-glia finding is an EVER 2025 abstract by Anne Rombaut and colleagues titled Galectin-3 is associated with Müller cells in glaucoma. I could not independently verify the exact full-text August 2026 Acta Neuropathologica Communications citation described in the prompt through the indexed records available for this review. That distinction matters. The abstract provides the central findings, but it does not provide all the information normally expected from a complete research article, such as the full donor characteristics, exact sample sizes, fold changes, complete statistical tables, and detailed limitations. The conclusions below therefore separate: Human tissue findings that are directly reported in the abstract Animal treatment findings from peer-reviewed studies Reasonable but still unproven interpretations The human findings are nevertheless important because they connect the Galectin-3 pathway to the cell type that spans almost the entire retina and supports retinal ganglion-cell metabolism and homeostasis. () What Researchers Found in Human Glaucomatous Retinas Galectin-3 increased in association with glial markers Rombaut and colleagues examined Galectin-3 staining in: A rat bead model of ocular hypertension at an early time point and an early degenerative time point Donor human retinas with late-stage glaucoma Cell cultures of human MIO-M1 Müller glial cells They compared Galectin-3 with: Iba-1, a marker used to identify microglia and infiltrating monocyte-lineage cells Glial fibrillary acidic protein, a marker expressed by reactive astrocytes and Müller glia In the experimental rat retinas, the volume of Galectin-3 staining and its overlap with both the micr

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us